Find your people Independent reporting · Context · Culture
Private unlicensed cannabis dispensing in England rose sharply in 2025. The figure shows a rapidly expanding market—but not 1.7 million patients, NHS access or proof of clinical benefit.
The FSA has backed the first three high-purity CBD novel-food applications for ministerial approval. It is a regulatory milestone—not permission for medicinal claims or every CBD product on sale.
A plant-derived dronabinol ingredient is now being offered through a UK specials manufacturer. It could widen formulation options, but it is not a newly licensed medicine or an NHS access breakthrough.
The US Drug Enforcement Administration has asked its judge to recommend Schedule III after a landmark hearing. It is a major institutional shift, but not yet a final nationwide rule.
Jersey’s licensed growers want to turn local crops into finished medicines on-island. The economic case is easy to see; the regulatory case must come first.
A major prospective study is tracking movement, sleep, cognition and daily life in older adults with chronic pain. Its design reflects a better question: does treatment help people function?
Recent studies suggest some prescribed-cannabis patients feel better able to sleep, connect and participate in daily life. The signal is encouraging—but it is not yet proof of cause and effect.
A controlled trial found that 800 mg of CBD reduced neuropathic pain after spinal-cord injury—but the average benefit was modest and the dose was far removed from retail CBD oil.
New US surveillance identified almost 200,000 emergency visits involving cannabinoid hyperemesis syndrome—but a coding change explains much of the apparent jump.
A controlled trial found that oral dronabinol reduced PTSD-related nightmares. The result is important—but it is not evidence that cannabis treats PTSD as a whole.
A controlled trial found that a precise THC/CBD formulation reduced agitation in advanced dementia. The result deserves attention—and careful limits.
Devon’s new inpatient procedure is welcome, but Cornwall already had a public pathway. The real story is why the NHS still lacks a consistent national standard.
The Government said the ACMD’s review of medical-cannabis legislation was expected in summer 2026. As publication is awaited, these are the tests that should define its value.
An Essex fire-service disclosure offers a rare look inside a safety-critical drug-testing policy—and shows why a positive result should begin a medical review, not end one.
Brazil’s regulator has clarified a revised pathway for manufacturing and importing medical cannabis products. The model protects access, but keeps the category deliberately temporary.
A newly published trial protocol will test whether medicinal cannabis improves quality of life and symptom control in advanced cancer. It is promising research, not a result.
A new systematic review finds that pure CBD is not the main problem. Undeclared THC, inconsistent products and blunt testing policies are where the real risk sits.
Medical cannabis patients can face uncertainty because THC may remain detectable after impairment has passed. The law provides a medical defence, but patients and clinicians continue to call for clearer, evidence-led rules.
The Mighty+ is the closest thing UK medical cannabis has to a reference vaporiser. We break down what makes it the clinic standard — and whether the £300 price tag is justified for patients.
Being a prescribed cannabis patient and an employee should not be incompatible. But UK employment law has yet to catch up with medical reality. Here's what patients need to know about their rights, their risks, and how to navigate disclosure.
The Ganja Club Weekly Digest This week, the most significant development in medical cannabis comes not from a clinical trial or a regulatory filing, but from the voices of patients themselves. A growing body of evidence suggests that lived experience is proving a more powerfu...
From the clinic-grade Mighty+ to the budget-friendly XMAX V3 Pro, we tested the five dry-herb vaporisers that UK patients actually rate. Not a single conduction pen made the cut.
Birmingham is the UK's second city, and its residents have full access to every UK cannabis clinic. Here is how the system works, which clinics serve the Midlands, and what your first step should be.
London has more prescribing clinics than anywhere else in the UK — but most Londoners still do not know medical cannabis is legal. Here is how the system works in the capital, which clinics serve London patients, and what your first step should be.
Manchester patients can access every UK cannabis clinic via video consultation — no travel required. Here is how the system works, which clinics best serve the North West, and what your first step should be.
From German pilot programmes to Czech legalisation and French medical trials, European cannabis reform is accelerating. We examine the patchwork of policies reshaping access across the continent.
Eight years after legalisation, the gap between policy and practice in UK medical cannabis has never been wider. We examine the cost, geography, and bureaucracy that keep patients from the treatment they are legally entitled to.
The Home Office has launched a review of medical cannabis licensing that could reshape how UK patients access treatment. Here is what the proposed reforms mean for patients, clinics, and the future of medical cannabis in Britain.
The VENTY is Storz & Bickel's newest and most powerful portable vaporiser — 20-second heat-up, adjustable airflow, and a 130-watt heater in your hand. We put it through its paces for medical cannabis patients.
Five years ago, telling your employer you had a cannabis prescription was unthinkable for most patients. Today, something is changing — in workplaces, in families, in the public conversation. The shift is slow, uneven, and real.
As the global cannabis industry expands, so does its environmental footprint. Indoor cultivation is energy-intensive, water use is high, and packaging waste is mounting. Can the industry's growth be reconciled with its environmental responsibilities?
The Volcano Hybrid is the clinical gold standard for desktop vaporisers. At £500+, it is a serious investment — here is what you are actually paying for and whether it makes sense for a UK medical cannabis patient.
Cancer patients represent one of the largest groups seeking prescribed cannabis in the UK. The evidence for symptom management is strong. The evidence for anti-tumour effects is not. Here's what patients and families need to understand.
Sleep disturbance is one of the most common reasons patients cite for using medical cannabis. The research paints a complex picture: cannabis can help you fall asleep faster, but it may also alter sleep architecture in ways that matter.
The Crafty+ is the smallest and most affordable Storz & Bickel portable — same vapour quality as the Mighty+ in a genuinely pocketable body. We review it for UK medical cannabis patients who need portability without compromise.
Launched in 2020 to build the UK's largest body of evidence on medical cannabis, Project Twenty21 aimed to enrol 20,000 patients by 2021. Five years on, what has the project achieved — and where has it fallen short?
The legal position on driving with prescribed cannabis is more nuanced than 'don't do it.' UK patients have a statutory medical defence — but the reality on the roadside is more complicated. Here's what you need to know.
At Cannabis Europa London 2026, held in May, delegates confronted a stark divide: the EU races toward regulatory harmonisation and adult-use reform, while the UK remains mired in a stalled medical programme. Investment is flowing east, and the conversation has shifted from ‘if’ to ‘when’ for adult-use in countries like the Czech Republic and the Netherlands.
Behind every prescription is a person who exhausted every other option. Three UK medical cannabis patients share their journeys through conventional medicine, stigma, and finally — relief.
THC and CBD dominate the conversation, but cannabis contains over 100 cannabinoids. CBG, CBN, CBC, and THCV are emerging as therapeutic compounds in their own right. Here's what the research tells us so far.
Private cannabis treatment isn't cheap, but the numbers might surprise you. From consultation fees to monthly prescription costs, here's what UK patients actually pay — and where the system could do better.
Private clinics widened access where the NHS did not. Their long-term credibility now depends on transparent oversight and consistently good care.
The UK medical cannabis market is expanding rapidly, but significant barriers remain for patients. A comprehensive look at where things stand in May 2026.
Patients report that stigma around cannabis as medicine remains one of the biggest challenges — often within the healthcare system itself.
Q1 2026 data projects US medical cannabis market to exceed $45 billion by 2027, with record sales but price compression squeezing multi-state operators in mature western states.
From Germany to Brazil, the global cannabis reform landscape is shifting rapidly. A roundup of the major policy developments you need to know.
Why we're here, what we stand for, and what you can expect from this publication. Medical cannabis news, analysis, and the culture that connects the community.
Beyond the clinics and the headlines, a new cannabis community is taking shape across the UK — one built on education, peer support, and shared experience.
From pain management to mental health, the clinical research pipeline for cannabinoid medicines is more active than ever. Here are the studies to watch.
Eight years after the law changed, NHS prescribing of cannabis-based medicines remains negligible. Here's what's blocking progress.
Germany's medical cannabis system has expanded rapidly since 2024 reforms. The UK could learn valuable lessons from its European neighbour.
Clinical research offers encouraging signals, but different conditions, doses and study designs make broad claims about CBD and anxiety premature.
The strongest case for NHS reform is not automatic prescribing; it is a fair clinical assessment that does not depend on a patient's income.
From private members' clubs to patient meetups, London's cannabis culture is maturing. A look at the community behind the medicine.
THC-based medicines may help some people with chronic pain, but variable benefits, side effects and limited long-term data demand a measured reading.
The European medical cannabis market has surpassed €2 billion in annual revenue for the first time, driven by surging demand in Germany, the UK, Poland, and Italy. With domestic cultivation scaling up and insurance reimbursement expanding, the sector is poised for continued growth into 2027.
The Home Office's position on cannabis scheduling continues to draw criticism from clinicians, researchers, and patient groups.
A practical guide to accessing medical cannabis through a private UK clinic — what to expect, how much it costs, and how to choose a clinic.
Terpenes — the aromatic compounds in cannabis — are emerging as a key area of research with potential therapeutic applications.
Delaware became the 25th US state to legalise adult-use cannabis sales on 15 April 2026, with three retailers opening under a social equity-focused licensing programme.
Anxiety disorders affect one in six UK adults. For some, prescribed cannabis provides relief where SSRIs and therapy have fallen short. The clinical evidence is more nuanced than advocates or sceptics tend to admit.
A year after Germany launched its second pillar of adult-use cannabis reform, the regional pilot programmes are yielding mixed results. Home cultivation and social clubs have found their feet, but commercial supply chains face regulatory hurdles that offer key lessons for the rest of Europe.
Bipartisan legislation and a $25 million VA funding push could finally allow doctors to recommend medical cannabis to veterans in legal states.
In early 2026, the Czech Republic unveiled draft legislation for a regulated adult-use cannabis market, drawing inspiration from Germany’s model while tailoring provisions to local priorities. The move, paired with a major expansion of the medical programme, is reshaping Central Europe’s cannabis landscape and setting a potential timeline for legal sales by late 2027.
Raising medical cannabis with a GP can feel daunting. Many patients report being dismissed or met with silence. Here's how to approach the conversation with confidence, evidence, and a clear record of what you've already tried.
The SAFE Banking Act has been reintroduced in the US Senate with a key Section 280E reform amendment, advancing through committee hearings with bipartisan support.
Every human body runs on a molecular signalling network most people have never heard of. The endocannabinoid system regulates sleep, mood, appetite, pain, and immune response — and medical cannabis works because it speaks the same chemical language.
FDA releases March 2026 draft guidance on hemp-derived CBD, proposing a 20 mg daily cap and strict labelling rules for a $4B+ market.
DEA hearings in March 2026 weigh historic move of cannabis to Schedule III, with HHS and DEA officials clashing over medical use and public health risks.